4D Molecular Therapeutics Inc logo

4D Molecular Therapeutics Inc

NAS:FDMT (USA)  
$ 12.64 -0.38 (-2.92%) 08:08 PM EST
P/E:
At Loss
P/B:
1.63
Market Cap:
$ 531.55M
Enterprise V:
$ 252.82M
Volume:
371.11K
Avg Vol (2M):
299.83K
Volume:
371.11K
Market Cap $:
531.55M
PE Ratio:
At Loss
Avg Vol (2M):
299.83K
Enterprise Value $:
252.82M
PB Ratio:
1.63

Business Description

Description
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
Name Current Vs Industry Vs History
Cash-To-Debt 19.86
Equity-to-Asset 0.92
Debt-to-Equity 0.05
Debt-to-EBITDA -0.14
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 10.75
Distress
Grey
Safe
Beneish M-Score -3.31
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 3.19
9-Day RSI 9.95
14-Day RSI 17.23
6-1 Month Momentum % 0.72
12-1 Month Momentum % 87.74

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 23.11
Quick Ratio 23.11
Cash Ratio 22.57

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -30
Shareholder Yield % -68.24

Financials (Next Earnings Date:2023-11-08 Est.)

FDMT's 30-Y Financials
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:FDMT

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

4D Molecular Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 2.284
EPS (TTM) ($) -3.28
Beta 0
Volatility % 182.86
14-Day RSI 17.23
14-Day ATR ($) 0.710871
20-Day SMA ($) 15.2235
12-1 Month Momentum % 87.74
52-Week Range ($) 6.58 - 26.49
Shares Outstanding (Mil) 42.05

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

4D Molecular Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

4D Molecular Therapeutics Inc Stock Events

Event Date Price($)
No Event Data

4D Molecular Therapeutics Inc Frequently Asked Questions

What is 4D Molecular Therapeutics Inc(FDMT)'s stock price today?
The current price of FDMT is $12.64. The 52 week high of FDMT is $26.49 and 52 week low is $6.58.
When is next earnings date of 4D Molecular Therapeutics Inc(FDMT)?
The next earnings date of 4D Molecular Therapeutics Inc(FDMT) is 2023-11-08 Est..
Does 4D Molecular Therapeutics Inc(FDMT) pay dividends? If so, how much?
4D Molecular Therapeutics Inc(FDMT) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1